USA - engelska - NLM (National Library of Medicine)

carilion materials management - guanfacine hydrochloride (unii: pml56a160o) (guanfacine - unii:30omy4g3mk) - guanfacine tablets, usp are indicated in the management of hypertension. guanfacine tablets, usp may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. guanfacine tablets are contraindicated in patients with known hypersensitivity to guanfacine hydrochloride. no reported abuse or dependence has been associated with the administration of guanfacine.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 4.56 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid; indigo carmine aluminium lake; iron oxide yellow - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 3.42 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid; indigo carmine aluminium lake; iron oxide yellow - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 2.28 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 1.14 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Kanada - engelska - Health Canada

angita pharma inc. - guanfacine (guanfacine hydrochloride) - tablet (extended-release) - 2mg - guanfacine (guanfacine hydrochloride) 2mg

Kanada - engelska - Health Canada

angita pharma inc. - guanfacine (guanfacine hydrochloride) - tablet (extended-release) - 3mg - guanfacine (guanfacine hydrochloride) 3mg

Kanada - engelska - Health Canada

angita pharma inc. - guanfacine (guanfacine hydrochloride) - tablet (extended-release) - 4mg - guanfacine (guanfacine hydrochloride) 4mg

Kanada - engelska - Health Canada

angita pharma inc. - guanfacine (guanfacine hydrochloride) - tablet (extended-release) - 1mg - guanfacine (guanfacine hydrochloride) 1mg

USA - engelska - NLM (National Library of Medicine)

tya pharmaceuticals - guanfacine hydrochloride (unii: pml56a160o) (guanfacine - unii:30omy4g3mk) - guanfacine 2 mg - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as monotherapy and as adjunctive therapy to stimulant medications. the efficacy of intuniv was studied for the treatment of adhd in three controlled monotherapy clinical trials (up to 8 weeks in duration) and one controlled adjunctive trial with psychostimulants (8 weeks in duration) in children and adolescents ages 6-17 who met dsm-iv criteria for adhd [ ]. the effectiveness of intuniv for longer-term use (more than 8 weeks) has not been systematically evaluated in controlled trials. ® ® ® see clinical studies (14) ® patients with a history of hypersensitivity to intuniv , its inactive ingredients or other products containing guanfacine should not take intuniv . ® [ ] see description (11) ® pregnancy category b risk summary there are no adequate and well-controlled studies of intuniv in pregnant women.  no fetal harm was observed in